ERBB2 and congenital rubella syndrome: Several BAT cell products have proven safe in multiple clinical trials without severe CRS, neurotoxicity, or organ toxicities, including anti-GD2/anti-CD3 (hu3F8 linked with mouse OKT3) [50], anti-HER2/anti-CD3 (trastuzumab linked with mouse OKT3) [51], and anti-EGFR/anti-CD3 (cetuximab linked with mouse OKT3) [52].